Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Rigel Pharmaceuticals, Inc is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Rigel Pharmaceuticals employs 163 staff and has a trailing 12-month revenue of around USD$105.6 million.
Since the stock market crash in March caused by coronavirus, Rigel Pharmaceuticals's share price has had significant positive movement.
Its last market close was USD$2.74, which is 16.06% up on its pre-crash value of USD$2.3 and 122.76% up on the lowest point reached during the March crash when the shares fell as low as USD$1.23.
If you had bought USD$1,000 worth of Rigel Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$612.43 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,173.46.
|Latest market close||USD$2.74|
|52-week range||USD$1.23 - USD$3.89|
|50-day moving average||USD$2.5769|
|200-day moving average||USD$2.3205|
|Wall St. target price||USD$7.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.352|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-16)||2.74|
|1 month (2020-10-26)||12.30%|
|3 months (2020-08-24)||15.13%|
|6 months (2020-05-22)||50.55%|
|1 year (2019-11-22)||19.13%|
|2 years (2018-11-23)||-0.36%|
|3 years (2017-11-24)||-35.53%|
|5 years (2015-11-24)||-12.18%|
|Revenue TTM||USD$105.6 million|
|Gross profit TTM||USD$5.5 million|
|Return on assets TTM||-12.31%|
|Return on equity TTM||-46.23%|
|Market capitalisation||USD$451.2 million|
TTM: trailing 12 months
There are currently 24.4 million Rigel Pharmaceuticals shares held short by investors – that's known as Rigel Pharmaceuticals's "short interest". This figure is 18% up from 20.7 million last month.
There are a few different ways that this level of interest in shorting Rigel Pharmaceuticals shares can be evaluated.
Rigel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rigel Pharmaceuticals shares currently shorted divided by the average quantity of Rigel Pharmaceuticals shares traded daily (recently around 2.3 million). Rigel Pharmaceuticals's SIR currently stands at 10.78. In other words for every 100,000 Rigel Pharmaceuticals shares traded daily on the market, roughly 10780 shares are currently held short.
However Rigel Pharmaceuticals's short interest can also be evaluated against the total number of Rigel Pharmaceuticals shares, or, against the total number of tradable Rigel Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rigel Pharmaceuticals's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Rigel Pharmaceuticals shares in existence, roughly 140 shares are currently held short) or 0.1674% of the tradable shares (for every 100,000 tradable Rigel Pharmaceuticals shares, roughly 167 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Rigel Pharmaceuticals.
Find out more about how you can short Rigel Pharmaceuticals stock.
We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.
Rigel Pharmaceuticals's shares were split on a 1:9 basis on 25 June 2003. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.
Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $1.23 up to $3.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 1.4064. This would suggest that Rigel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trials for warm autoimmune hemolytic anemia; R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trials for autoimmune and inflammatory diseases; and R552, a receptor-interacting protein kinase Inhibitor that is in phase I clinical trials for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Steps to owning and managing SELF, with 24-hour and historical pricing before you buy.
Steps to owning and managing GLP, with 24-hour and historical pricing before you buy.
Steps to owning and managing FRGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXFO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ESRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLOW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FOF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing CGNX, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.